Truist Securities Maintains Buy on Chemours, Lowers Price Target to $18
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $20 to $18.
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $20 to $18.